Showing 1 - 10 of 48
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
Persistent link: https://www.econbiz.de/10001482065
Persistent link: https://www.econbiz.de/10000647168
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10010270528
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010283600
Persistent link: https://www.econbiz.de/10001619498
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% - from 69,7 to 76,5 years - and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...
Persistent link: https://www.econbiz.de/10001566397
Persistent link: https://www.econbiz.de/10001695895
Persistent link: https://www.econbiz.de/10000651512
Persistent link: https://www.econbiz.de/10001719206